1. Mullard Asher (2013) Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discovery 12:329–332
2. Lin Tibbitts (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2353–2366
3. Leipold D, Bender B, Xu K, Theil F-P, and Tibbitts J (2009) Understanding the de-conjugation of Trastuzumab-MCC-DM1 through application of a multi-compartmental model of individual drug: antibody species in cynomolgus monkey. Presented at the 2009 American Association for Cancer Research (AACR) Meeting, Denver, Colorado
4. Bender B, Leipold D, Liu L, Xu K, Shen B-Q, Friberg LE, Tibbitts J. A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer, Page 21 (2012) Abstr 2607 [ www.page-meeting.org/?abstract=2607 ]
5. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Sandhya Girish S, An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 52(8):657-672